NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

The firm has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same offering price per share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.